Novartis

Novartis

Verified
To discover, develop and successfully market innovative products to prevent and cure diseases, to ease suffering

Launch date
Employees
Market cap
$166.3b
Net debt
($11.3b)
Firm valuation
$177.6b (Public information from Sep 2022)
Basel Canton of Basel-Stadt (HQ)

Financials

Edit
Revenues, earnings & profits over time
EUR2016201720182019202020212022E
Revenues-44.6b47.2b43.1b44.2b46.9b48.6b
% growth--6 %(9 %)3 %6 %4 %
EBITDA-13.2b14.2b14.4b15.3b16.6b16.8b
% EBITDA margin-30 %30 %33 %35 %35 %35 %
Profit-7.0b11.5b6.5b7.3b21.8b8.9b
% profit margin-16 %24 %15 %17 %47 %18 %
R&D budget8.5b7.3b8.0b7.7b---
R&D % of revenue-16 %17 %18 %---

Source: Company fillings or news article

  • Edit
DateInvestorsAmountRound
-N/A-
Not yet verified
$6.5mGrant
Total Funding$6.5m

Recent News about Novartis

Edit

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.
Investments analysisEdit
  • Edit
Ziarco Pharma
ACQUISITION by Novartis Dec 2016
Encore Vision Inc.
ACQUISITION by Novartis Dec 2016
Corthera
ACQUISITION by Novartis Dec 2009
SomaLogic
exited
The Medicines Company
ACQUISITION by Novartis Nov 2019
Endocyte
ACQUISITION by Novartis Nov 2018
View 175 more